COMMUNIQUÉS West-GlobeNewswire

Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024
28/05/2024
CORAL GABLES, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and [...]
Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
28/05/2024
Key Findings: 92.3% Sensitivity for Colorectal Cancer, 82.3% for Advanced Precancerous Lesions Poster presentation showing new data on 690 subjects including previously unexamined and unreported samples from the pooled [...]
Spectral AI to Participate in Benzinga’s “AI Unleashed: Exploring the Possibilities” Virtual Event
28/05/2024
DALLAS, May 28, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment [...]
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
28/05/2024
FLORHAM PARK, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) [...]
Avalyn to Participate in Jefferies Global Healthcare Conference
28/05/2024
CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. , a clinical-stage biopharmaceutical company focused on development of inhaled therapies for life-threatening pulmonary diseases, today announced [...]
HiberCell Announces First Patient Dosed in Phase 1b Clinical Trial, Evaluating HC-7366 in Combination with Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia (AML)
28/05/2024
BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address advanced cancer and cancer resistance, is pleased to announce the first patient dosed [...]
PetMed Express, Inc. Appoints Carla Dodds as New Chief Marketing Officer
28/05/2024
Accomplished executive will lead integrated marketing strategy to accelerate growth DELRAY BEACH, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- PetMed Express, Inc. , dba PetMeds and parent company of PetCareRx, (Nasdaq: PETS [...]
Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)
28/05/2024
BRISBANE, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients [...]
Aummune’s Poster at ASCO 2024 to Highlight Ongoing Phase 1 Trial for AM003
28/05/2024
AM003 is a first-in-class functional oligonucleotide in development for the treatment of solid tumors Trial-in-Progress poster to provide an overview of the Phase 1 dose-escalation study with AM003 in patients with [...]
DLH Announces Participation in Upcoming Events
28/05/2024
ATLANTA, May 28, 2024 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”) , a leading provider of science research and development, systems engineering and integration, and digital [...]
Bionano Announces Private Placement of Senior Secured Notes in Debt Restructuring that Improves Balance Sheet
28/05/2024
Provides significant financial flexibility by retiring near-term debt maturities, deferring principal redemption payments, and further reducing near-term cash needs SAN DIEGO, May 28, 2024 (GLOBE NEWSWIRE) -- Bionano [...]
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)
28/05/2024
MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, [...]
Neurona Therapeutics to Participate in Jefferies Global Healthcare Conference
28/05/2024
SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Neurona Therapeutics , a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for the potential treatment of neurological disorders, [...]
Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data At 2024 Eastern Allergy Conference
28/05/2024
WARREN, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives [...]
REPEAT – Large Protests This Week Across Ontario in Response to Ford Government’s Health Care Privatization & Closures of Local Hospitals
28/05/2024
TORONTO, May 28, 2024 (GLOBE NEWSWIRE) -- Raising the alarm about the urgent threat to public health care, the Ontario Health Coalition is mobilizing thousands of Ontarians to fightback against the Ford government’s [...]
Nanox Announces First Quarter of 2024 Financial Results and Provides Business Update
28/05/2024
Accelerates Deployment of Nanox.ARC in United States Signed two commercial agreements for Nanox.AI Management to host conference call and webcast Tuesday, May 28, 2024 at 8:30 AM ET PETAH TIKVA, Israel, May 28, 2024 ( [...]
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study
28/05/2024
Study to evaluate the effects of Bria-OTS™ in combination with anti-PD-1 antibody tislelizumab, in advanced, late stage, heavily pretreated metastatic breast cancer. PHILADELPHIA and VANCOUVER, British Columbia, May 28 [...]
HealthLynked Introduces AI-Powered Chat Function to Enhance Healthcare Accessibility
28/05/2024
NAPLES, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp. ( OTCQB: HLYK ), a leading innovator in healthcare technology, is thrilled to announce the launch of its new AI-powered chat function designed [...]
Tonix Pharmaceuticals Announces Presentation at the 2024 BIO International Convention
28/05/2024
Presentation to highlight statistically significant Phase 3 results of Tonmya™ for the management of fibromyalgia New Drug Application (NDA) submission to the FDA on track for the second half of 2024 CHATHAM, N.J., May [...]

Pages